Page last updated: 2024-10-30
memantine and Common Migraine
memantine has been researched along with Common Migraine in 1 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " Sixty patients with migraine without aura were randomized using a computer-generated list to receive memantine (10 mg/day) or placebo for 12 weeks." | 9.22 | Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study. ( Aghamollaii, V; Ghaffarpour, M; Harirchian, MH; Modabbernia, A; Nikbakht, N; Noruzi, N; Noruzzadeh, R; Salahi, S; Tafakhori, A, 2016) |
| " Sixty patients with migraine without aura were randomized using a computer-generated list to receive memantine (10 mg/day) or placebo for 12 weeks." | 5.22 | Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study. ( Aghamollaii, V; Ghaffarpour, M; Harirchian, MH; Modabbernia, A; Nikbakht, N; Noruzi, N; Noruzzadeh, R; Salahi, S; Tafakhori, A, 2016) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Noruzzadeh, R | 1 |
| Modabbernia, A | 1 |
| Aghamollaii, V | 1 |
| Ghaffarpour, M | 1 |
| Harirchian, MH | 1 |
| Salahi, S | 1 |
| Nikbakht, N | 1 |
| Noruzi, N | 1 |
| Tafakhori, A | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Efficacy of Memantine Compared With Sodium Valproate in the Prophylactic Treatment of Episodic Migraine.[NCT04698525] | Phase 3 | 33 participants (Actual) | Interventional | 2019-02-15 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Measure Changes in Weight With the Administration of Active Drugs.
To compare the average weight in both arms before and after Valproate and Memantine administration. The weight will be measured in kilograms, and the initial against the final will be compared. (NCT04698525)
Timeframe: Three months
| Intervention | kilograms (Mean) |
|---|
| Pre-treatment | Post-treatment |
|---|
| Memantine | 64.44 | 64.19 |
,| Valproate Group | 71.77 | 72.13 |
Reduction in Days of Headache Pain With Treatment of Memantine or Valproate in the Preventive Management of Episodic Migraine.
In a double-blind clinical trial, we compared two active drugs (mamantine vs. valproate) three months after initiation, looking for changes in the average number of days of migraine attack presentation per month and comparing the three months before with the three months after treatment administration with two active drugs. (NCT04698525)
Timeframe: Three months before treatment (Pretreatment), three months after initiating treatment (post-treatment)
| Intervention | Migraine days by month. (Mean) |
|---|
| Pretreatment | Post-treatment |
|---|
| Memantine | 5.31 | 0.93 |
,| Valproate Group | 5.35 | 0.77 |
The Change in the Intensity of the Pain in a Migraine Attack Will be Measured by a Visual Analogue Scale (VAS).
"The possible reduction in the average on the visual analog scale (0-10) comparing three months before and after three months of the treatment with both drugs. We measured both arms of the study.~0 means without pain. 10 means the worst possible pain in the concept of the patient." (NCT04698525)
Timeframe: Three months previous and three months after the treatment.
| Intervention | Score on a scale (Mean) |
|---|
| Pre-treatment | Post-treatment |
|---|
| Memantine | 8.5 | 4.28 |
,| Valproate Group | 8.94 | 2.5 |
The Migraine Disability Assessment MIDAS Scale Will Measure Before and After the Treatment to Improve the Quality of Life in Both Groups After Three Months of Treatment.
"To compare the average of Memantine against the group that receives Valproate before and after starting preventive treatment. Using the Migraine Disability Assessment scale (The score is the sum of days missed from work or school, days of housework missed, days of missed non-work activities, and days of work or school plus days of housework in which productivity in the last three months) to compare punctuation changes. The MIDAS score is divided into four degrees, the minimum score is 0 points, and the maximum score is 70. A higher value represents a higher difficulty to carry out a satisfactory lifestyle, and a score higher than 20 points already represents a high limitation to enjoying daily activities:~Grade I (0-5 points): Slight limitations and few patient treatment needs. Grade II (6-10 points): Moderate limitations and treatment needs. Grade III (11-20 points) and IV (21 or more points): Severe and significant punctuation treatment needs." (NCT04698525)
Timeframe: Three months.
| Intervention | score on a scale (Mean) |
|---|
| Pre-treatment | Post-treatment |
|---|
| Memantine | 60.87 | 15.57 |
,| Valproate Group | 51.92 | 10.53 |
Trials
1 trial available for memantine and Common Migraine